Biomoda has secured $2 million in funding from three hedge funds to conduct further clinical trials of a diagnostic test to detect lung cancer. "Proceeds from the financing will allow us to continue our clinical trials, submit our findings to the FDA for clearance as a Class III medical device and begin commercialization," said John Cousins, Biomoda's president and CEO.

Related Summaries